Current perspectives on nasopharyngeal carcinoma
Abstract Of the~ 129,079 new cases of nasopharyngeal carcinoma (NPC) and 72,987
associated deaths estimated for 2018, the majority will be geographically localized to South …
associated deaths estimated for 2018, the majority will be geographically localized to South …
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
FI Nollmann, DA Ruess - Biomedicines, 2020 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal cancers with a dismal
prognosis for the patient. This is due to limited diagnostic options for the early detection of …
prognosis for the patient. This is due to limited diagnostic options for the early detection of …
Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment
Y Jin, X An, B Mao, R Sun, R Kumari, X Chen… - Scientific Reports, 2022 - nature.com
Cancers are immunologically heterogeneous. A range of immunotherapies target abnormal
tumor immunity via different mechanisms of actions (MOAs), particularly various tumor …
tumor immunity via different mechanisms of actions (MOAs), particularly various tumor …
Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer
KR Zhang, YF Zhang, HM Lei, YB Tang… - Science translational …, 2021 - science.org
Acquired resistance represents a bottleneck to molecularly targeted therapies such as
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in lung …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in lung …
HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
H Ke, F Zhang, J Wang, L Xiong, X An, X Tu, C Chen… - Scientific Reports, 2023 - nature.com
Abstract Both PD1/PD-L1 and CD47 blockades have demonstrated limited activity in most
subtypes of NHL save NK/T-cell lymphoma. The hemotoxicity with anti-CD47 agents in the …
subtypes of NHL save NK/T-cell lymphoma. The hemotoxicity with anti-CD47 agents in the …
The design, analysis and application of mouse clinical trials in oncology drug development
Abstract Background Mouse clinical trials (MCTs) are becoming wildly used in pre-clinical
oncology drug development, but a statistical framework is yet to be developed. In this study …
oncology drug development, but a statistical framework is yet to be developed. In this study …
Design and rationale for a phase II, randomized, open-label, two-cohort multicenter interventional study of Osimertinib with or Without Savolitinib in de novo MET …
A Li, HJ Chen, JJ Yang - Clinical Lung Cancer, 2023 - Elsevier
Introduction Epidermal growth factor receptor (EGFR) mutations are well-known genetic
alterations in advanced non-small cell lung cancer (NSCLC) which are associated with …
alterations in advanced non-small cell lung cancer (NSCLC) which are associated with …
Humanized Mouse Models for Immuno‐oncology Drug Discovery
R Kumari, G Feuer, L Bourré - Current Protocols, 2023 - Wiley Online Library
Breakthroughs in cancer treatment with immunotherapeutics have provided long‐term
patient benefits for many different types of cancer. However, complete response is not …
patient benefits for many different types of cancer. However, complete response is not …
Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways
J Tang, L Karhinen, T Xu, A Szwajda… - PLoS computational …, 2013 - journals.plos.org
A recent trend in drug development is to identify drug combinations or multi-target agents
that effectively modify multiple nodes of disease-associated networks. Such …
that effectively modify multiple nodes of disease-associated networks. Such …
A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
L Zhang, J Yang, J Cai, X Song, J Deng, X Huang… - Scientific reports, 2013 - nature.com
A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts
responded to cetuximab. Genome-wide profiling and additional investigations revealed that …
responded to cetuximab. Genome-wide profiling and additional investigations revealed that …